ECSP045239A - Composicion de ziprasidona y controles sinteticos - Google Patents

Composicion de ziprasidona y controles sinteticos

Info

Publication number
ECSP045239A
ECSP045239A EC2004005239A ECSP045239A ECSP045239A EC SP045239 A ECSP045239 A EC SP045239A EC 2004005239 A EC2004005239 A EC 2004005239A EC SP045239 A ECSP045239 A EC SP045239A EC SP045239 A ECSP045239 A EC SP045239A
Authority
EC
Ecuador
Prior art keywords
ziprasidone
ziprasidone composition
synthetic controls
composition
synthetic
Prior art date
Application number
EC2004005239A
Other languages
English (en)
Inventor
Frank Robert Busch
Adam Worth Grobin
Harry Ralph Howard
Kyle Robert Leeman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27761437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045239(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP045239A publication Critical patent/ECSP045239A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

El objeto de la invención proporciona una composición de ziprasidona que comprende no más que aproximadamente 1000 ppm de ziprasidona desclorada, preferiblemente no más que aproximadamente 500 ppm de ziprasidona desclorada, y más preferiblemente no más que aproximadamente 100 ppm de ziprasidona desclorada. Se proporcionan también procedimientos para sintetizar y utilizar dichas composiciones de ziprasidona.
EC2004005239A 2002-02-20 2004-08-19 Composicion de ziprasidona y controles sinteticos ECSP045239A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35880602P 2002-02-20 2002-02-20
US35903802P 2002-02-21 2002-02-21
US36045902P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
ECSP045239A true ECSP045239A (es) 2004-09-28

Family

ID=27761437

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005239A ECSP045239A (es) 2002-02-20 2004-08-19 Composicion de ziprasidona y controles sinteticos

Country Status (41)

Country Link
EP (1) EP1476162B1 (es)
JP (1) JP4554938B2 (es)
KR (1) KR100773622B1 (es)
CN (2) CN1635892A (es)
AP (1) AP2004003103A0 (es)
AR (1) AR038563A1 (es)
AT (1) ATE359787T1 (es)
AU (2) AU2003206035A1 (es)
BR (1) BR0307833A (es)
CA (1) CA2475302C (es)
CO (1) CO5611138A2 (es)
CY (1) CY1106467T1 (es)
DE (1) DE60313289T2 (es)
DK (1) DK1476162T3 (es)
EA (1) EA007866B1 (es)
EC (1) ECSP045239A (es)
ES (1) ES2283745T3 (es)
GE (1) GEP20074030B (es)
GT (1) GT200300040A (es)
HR (1) HRP20040711A2 (es)
IL (1) IL163277A (es)
IS (1) IS7344A (es)
MA (1) MA27177A1 (es)
MX (1) MXPA04006993A (es)
MY (1) MY139523A (es)
NO (2) NO20043902L (es)
NZ (1) NZ534443A (es)
OA (1) OA12774A (es)
PA (1) PA8567001A1 (es)
PE (1) PE20030942A1 (es)
PL (1) PL372238A1 (es)
PT (1) PT1476162E (es)
RS (1) RS60404A (es)
SI (1) SI1476162T1 (es)
SV (1) SV2004001485A (es)
TN (1) TNSN04159A1 (es)
TW (1) TW200307546A (es)
UA (1) UA77057C2 (es)
UY (1) UY27668A1 (es)
WO (1) WO2003070246A1 (es)
ZA (1) ZA200406276B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU780006B2 (en) 2000-03-06 2005-02-24 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
NZ571695A (en) 2001-12-28 2010-02-26 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
MXPA04012893A (es) 2002-06-24 2005-03-31 Acadia Pharm Inc Derivados de piperidina n-substituidos como agentes receptores de serotonina.
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
PT1587789E (pt) 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
ATE393764T1 (de) 2003-03-17 2008-05-15 Teva Pharma Polymorphe formen von valsartan
TW200505879A (en) * 2003-04-21 2005-02-16 Teva Pharma Process for the preparation of valsartan
KR20080022595A (ko) 2003-06-03 2008-03-11 테바 파마슈티컬 인더스트리즈 리미티드 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
WO2005061493A2 (en) * 2003-12-18 2005-07-07 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
EP1720867B1 (en) 2004-02-27 2009-12-09 Ranbaxy Laboratories Limited Process for the preparation of ziprasidone
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
CA2580136C (en) 2004-09-27 2015-08-18 Acadia Pharmaceuticals Inc. Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
ES2250000B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Procedimiento para la preparacion de ziprasidona.
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US20090163513A1 (en) * 2005-01-27 2009-06-25 Hetero Drugs Limited Process for ziprasidone using novel intermediates
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
CN100491375C (zh) * 2006-07-01 2009-05-27 浙江美诺华药物化学有限公司 一种齐拉西酮的制备方法
CA2681506C (en) 2007-03-19 2016-05-24 Perry Peters Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
CN102234272A (zh) * 2010-04-21 2011-11-09 上海医药工业研究院 盐酸齐拉西酮半水合物的制备方法
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
CA2992728A1 (en) 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
CN108239085A (zh) * 2016-12-26 2018-07-03 四川科瑞德凯华制药有限公司 一种甲磺酸齐拉西酮的纯化及制备方法
EP3615028A1 (en) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CN112724066B (zh) * 2021-02-04 2022-10-21 海南鑫开源医药科技有限公司 一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法
CN116046966A (zh) * 2023-01-17 2023-05-02 北京协和建昊医药技术开发有限责任公司 一种流动相配置装置及其配置方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
WO1997017336A1 (en) 1995-11-07 1997-05-15 Pfizer Inc. Processes and intermediates for preparing 3-(1-piperazinyl)-1,2-benzisothiazole
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
DK0904273T3 (da) * 1996-05-07 2003-07-07 Pfizer Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
ZA200406276B (en) 2005-09-20
JP2005525347A (ja) 2005-08-25
JP4554938B2 (ja) 2010-09-29
GEP20074030B (en) 2007-02-12
DK1476162T3 (da) 2007-07-02
PT1476162E (pt) 2007-06-25
NZ534443A (en) 2007-07-27
WO2003070246A1 (en) 2003-08-28
EA200400815A1 (ru) 2004-12-30
BR0307833A (pt) 2004-12-07
AR038563A1 (es) 2005-01-19
IS7344A (is) 2004-07-05
UA77057C2 (en) 2006-10-16
ATE359787T1 (de) 2007-05-15
AU2003206035A1 (en) 2003-09-09
DE60313289T2 (de) 2007-12-27
MXPA04006993A (es) 2004-11-10
EP1476162A1 (en) 2004-11-17
MY139523A (en) 2009-10-30
KR20040086417A (ko) 2004-10-08
EA007866B1 (ru) 2007-02-27
NO20043902L (no) 2004-09-17
AU2009202008A1 (en) 2009-06-11
CN1635892A (zh) 2005-07-06
SV2004001485A (es) 2004-05-07
HRP20040711A2 (en) 2004-12-31
ES2283745T3 (es) 2007-11-01
AP2004003103A0 (en) 2004-09-30
NO20100584L (no) 2004-09-17
CA2475302C (en) 2009-05-12
KR100773622B1 (ko) 2007-11-05
UY27668A1 (es) 2003-10-31
TNSN04159A1 (fr) 2007-03-12
PE20030942A1 (es) 2003-11-08
RS60404A (sr) 2006-10-27
SI1476162T1 (sl) 2007-08-31
PA8567001A1 (es) 2003-12-10
TW200307546A (en) 2003-12-16
IL163277A (en) 2010-05-31
CY1106467T1 (el) 2012-01-25
CA2475302A1 (en) 2003-08-28
EP1476162B1 (en) 2007-04-18
MA27177A1 (fr) 2005-01-03
CO5611138A2 (es) 2006-02-28
PL372238A1 (en) 2005-07-11
DE60313289D1 (de) 2007-05-31
GT200300040A (es) 2007-01-12
CN101735212A (zh) 2010-06-16
OA12774A (en) 2006-07-04

Similar Documents

Publication Publication Date Title
ECSP045239A (es) Composicion de ziprasidona y controles sinteticos
ECSP034600A (es) Compuestos de lactama
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
CY1112950T1 (el) Νηματωδοκτονες συνθεσεις
ATE359279T1 (de) Moschus-geruchsstoffe
CY1105137T1 (el) Παραγωγα αμινοκυκλοεξυλ αιθερων και χρησεις τους
ATE293691T1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
CY1105980T1 (el) Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
MXPA06000888A (es) Composicion, toalla limpiadora y metodo para limpiar, proteger e impartir brillo a un substrato.
DE50310579D1 (de) Furancarboxamide
ATE315064T1 (de) Polyorganosiloxan-zusammensetzung
UA83203C2 (uk) Тіазол-(бі)циклоалкілкарбоксаніліди, засіб на їх основі та застосування для боротьби з небажаними мікроорганізмами
AR032548A1 (es) Metodo y composicion para desinfectar una superficie contaminada con una proteina prion
AU2003221053A1 (en) Unsaturated polybranched compounds, curable compositions containing the same and cured articles thereof
DE50311756D1 (de) Mikrobizide oxathiincarboxamide
IL173929A0 (en) Analogues of kahalalide f and pharmaceutical compositions containing the same
EA200500878A1 (ru) Кальцилитические соединения
DE50107490D1 (de) Stoffgemisch enthaltend bisphenol a
CU23343A3 (es) Composición de ziprasidona y controles sintéticos
CR7418A (es) Composicion de ziprasidona y controles sinteticos
ATE394105T1 (de) Substituierte 4,5-dihydro-1,2,4-triazin-3-one, 1, 2,4-triazin-3-one sowie deren verwendung als fungizide und insektizide
FR2842109B1 (fr) Utilisation d'un extrait de chrysanthellum
TW200500350A (en) Photochromic oxazine compounds and methods for their manufacture